The recent trade deal announced between the European Union and the United States has sparked a heated debate within the pharmaceutical industry. The European Federation of Pharmaceutical Industries (EFPIA) has voiced concerns about the potential impact of tariffs on medicines, emphasizing the disruptive effect on supply chains, research and development investments, and patient access to essential medications. Despite conflicting statements from the Trump administration regarding tariff imposition on pharmaceuticals, EU trade representatives have indicated that pharma imports from the U.S. will remain duty-free. This disagreement has raised questions about the compliance with international trade agreements, particularly the zero-tariff rating for medicines established by the World Trade Organization in 1995. The U.S.’s heavy reliance on European-made drugs, with Europe being the top exporter of pharmaceutical products to the U.S., further complicates the situation. The European Union has seen a significant increase in exports of medicinal and pharmaceutical products, underscoring the importance of the industry in transatlantic trade relations.
Read more from supplychainbrain.com